Skip to main content

Advertisement

Log in

Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

While breast cancer has historically been treated with surgery followed by adjuvant chemotherapy (AC) and radiation when indicated, neoadjuvant chemotherapy (NAC) use is thought to be increasing; however, the trends of its use in various biological subtypes have not been evaluated. We sought to evaluate the trend of NAC use over time by biological subtype.

Methods

We identified all patients with invasive breast cancer who underwent curative intent surgery and were treated with chemotherapy from 2010 to 2015 from the National Cancer Database. An unadjusted analysis of trends in proportions over time was performed using Cochran–Armitage trend tests stratified by hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status.

Results

Of 315,264 patients who received chemotherapy, 251,726 (79.8%) received AC and 63,538 (20.2%) received NAC. From 2010 to 2015, significant increases in NAC use were seen in all biologic subtypes (all p < 0.001). The highest proportions and greatest increases in proportions of NAC were seen among triple-negative breast cancers (TNBC; 19.5–33.7%) and HER2+ (HR−/HER2+, 21.5–39.8%; HR+/HER2+, 17.0–33.7%) tumors. HR+/HER2− tumors also had a statistically significant increase in use but this increase was less dramatic (13.0–16.8%) and NAC use in recent years was significantly lower than in other subtypes (p < 0.001).

Conclusion

Within patients receiving chemotherapy for breast cancer, its receipt in the neoadjuvant setting has been increasing among all biologic subtypes. The highest use of NAC is in TNBC and HER2+ disease, with use in these subgroups being twice as frequent as in HR+/HER2− disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Nandy A, Gangopadhyay S, Mukhopadhyay A. Individualizing breast cancer treatment: the dawn of personalized medicine. Exp Cell Res. 2014;320(1):1–11.

    Article  PubMed  CAS  Google Scholar 

  2. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483–93.

    Article  PubMed  CAS  Google Scholar 

  3. Untch M, Konecny GE, Paepke S, von Minckwitz G. Current and future role of neoadjuvant therapy for breast cancer. Breast. 2014;23(5):526–37.

    Article  PubMed  Google Scholar 

  4. Haddad TC, Goetz MP. Landscape of neoadjuvant therapy for breast cancer. Ann Surg Oncol. 2015;22(5):1408–15.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Loibl S, Denkert C, von Minckwitz G. Neoadjuvant treatment of breast cancer: clinical and research perspective. Breast. 2015;24 Suppl 2:S73–7.

    Article  PubMed  Google Scholar 

  6. Tanaka S, Iwamoto M, Kimura K, et al. A phase II study of adjuvant chemotherapy of tegafur-uracil for patients with breast cancer with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy. Anticancer Res. 2016;36(12):6505–9.

    Article  PubMed  CAS  Google Scholar 

  7. Mittendorf EA, Vila J, Tucker SL, et al. The neo-bioscore update for staging breast cancer treated with neoadjuvant chemotherapy: incorporation of prognostic biologic factors into staging after treatment. JAMA Oncol. 2016;2(7):929–36.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414–22.

    Article  PubMed  Google Scholar 

  9. Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014;260(4):608–14 (discussion 614–6).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Puig CA, Hoskin TL, Day CN, Habermann EB, Boughey JC. National trends in the use of neoadjuvant chemotherapy for hormone receptor-negative breast cancer: a National Cancer Data Base Study. Ann Surg Oncol. 2017;24(5):1242–50.

    Article  PubMed  Google Scholar 

  11. Mougalian SS, Soulos PR, Killelea BK, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015;121(15):2544–52.

    Article  PubMed  Google Scholar 

  12. Raval MV, Bilimoria KY, Stewart AK, Bentrem DJ, Ko CY. Using the NCDB for cancer care improvement: an introduction to available quality assessment tools. J Surg Oncol. 2009;99(8):488–90.

    Article  PubMed  Google Scholar 

  13. Edge S, Byrd D, Compton C. Breast Cancer. In: Edge S, Byrd D, Compton C, et al. (eds). AJCC cancer staging manual. New York: Springer; 2009.

    Google Scholar 

  14. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.

    Article  PubMed  Google Scholar 

  15. Wu K, Yang Q, Liu Y, Wu A, Yang Z. Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy. World J Surg Oncol. 2014;12:95.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Al-Hilli Z, Boughey JC, Hoskin TL, Heins CN, Hieken TJ. Increasing use of neoadjuvant treatment for T1 and T2 HER2-positive tumors. Ann Surg Oncol. 2015;22(10):3369–75.

    Article  PubMed  Google Scholar 

  17. Amiri-Kordestani L, Wedam S, Zhang L, et al. First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin Cancer Res. 2014;20(21):5359–64.

    Article  PubMed  CAS  Google Scholar 

  18. Ellis MJ, Suman VJ, Hoog J, et. al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype: ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Chiba A, Hoskin TL, Heins CN, Hunt KK, Habermann EB, Boughey JC. Trends in neoadjuvant endocrine therapy use and impact on rates of breast conservation in hormone receptor-positive breast cancer: a National Cancer Data Base Study. Ann Surg Oncol. 2017;24(2):418–24.

    Article  PubMed  Google Scholar 

  20. Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the primary therapy of early breast cancer 2017. Ann Oncol. 2017;28(8):1700–12.

    Article  PubMed  CAS  Google Scholar 

  21. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Breast Cancer. 2018; Vol. 1. 2018. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 5 Apr 2018.

  22. American Board of Internal Medicine. American College of Surgeons and Commission on Cancer Release Lists of commonly used tests and treatments for patients to discuss with their surgeons. 2013. http://www.choosingwisely.org/american-college-of-surgeons-and-commission-on-cancer-release-lists-of-commonly-used-tests-and-treatments-for-patients-to-discuss-with-their-surgeons/. Accessed 5 Apr 2018.

Download references

Funding

This research did not receive any specific grants from funding agencies in the public, commercial, or non-for-profit sectors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Judy C. Boughey MD, FACS.

Ethics declarations

Disclosure

Brittany L. Murphy, Courtney N. Day, Tanya L. Hoskin, Elizabeth B. Habermann, and Judy C. Boughey disclose no conflicts of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Electronic Supplementary Fig.

 1 Proportion of patients with stage II breast cancer receiving neoadjuvant chemotherapy versus adjuvant chemotherapy, stratified by biologic subtype and clinical nodal stage at presentation. AC adjuvant chemotherapy, HER2 human epidermal growth factor receptor 2, HR hormone receptor, NAC neoadjuvant chemotherapy, TNBC triple-negative breast cancer (PNG 238 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Murphy, B.L., Day, C.N., Hoskin, T.L. et al. Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes. Ann Surg Oncol 25, 2241–2248 (2018). https://doi.org/10.1245/s10434-018-6531-5

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-018-6531-5

Keywords

Navigation